Editor's Note: Patients with oligometastatic cervical cancer face a risk of systemic recurrence but may also benefit from aggressive local treatment. During ESMO 2026, results were reported from a Chinese single-arm Phase II study evaluating QL1706 plus chemotherapy, followed by definitive radiotherapy and continued immunotherapy maintenance. A total of 28 patients were enrolled. Among the 22 evaluable patients, the objective response rate (ORR) was 90.91%, and the disease control rate (DCR) was 100%. After a median follow-up of 8.25 months, median progression-free survival (PFS) had not yet been reached. Oncology Frontier invited Professor Peng Xie from Shandong Cancer Hospital and Institute, affiliated with Shandong First Medical University, to discuss the study design, efficacy findings, and safety management, and to share his perspectives on clinical practice.Oncology Frontier: This study investigated QL1706 plus chemotherapy followed by radiotherapy in patients with oligometastatic cervical cancer and achieved a high short-term response rate. Compared with conventional treatment, what do you consider the clinical significance of this comprehensive treatment approach?
Professor Peng Xie: Patients with oligometastatic cervical cancer have a limited number of lesions. Although they remain at risk of systemic recurrence, they may also benefit from aggressive local treatment. They should not simply be managed in the same way as patients with widely metastatic cervical cancer. Clinical decision-making needs to consider systemic therapy, definitive local treatment, and subsequent maintenance therapy together, with the aim of achieving more durable disease control.
This study enrolled patients aged 18–75 years with recurrent or metastatic cervical cancer and no more than five recurrent or metastatic lesions. Histological types included squamous cell carcinoma and adenocarcinoma. Patients first received four to six cycles of QL1706 plus paclitaxel and either cisplatin or carboplatin, followed by definitive radiotherapy. Radiotherapy modalities included intensity-modulated radiotherapy, proton therapy, stereotactic body radiotherapy (SBRT), and brachytherapy, with concurrent QL1706. After completion of local treatment, patients continued QL1706 maintenance therapy. The treatment sequence was designed to address systemic risk first, then treat visible lesions, and finally maintain disease control through immunotherapy.
Of course, oligometastatic disease does not mean that every patient is suitable for aggressive local treatment. Performance status, previous radiation fields, lesion distribution, involvement of critical organs, and whether all lesions can be safely included within a definitive radiation plan must be assessed before treatment. Comprehensive treatment is feasible only when both systemic and local therapies can be appropriately delivered. The value of this study lies in placing an important clinical question at the forefront of treatment decision-making: Which patients may benefit from definitive local treatment?
As of the May 2026 data cutoff, a total of 28 patients had been enrolled between February and October 2025. Of these, 15 had locoregional recurrence and 13 had distant metastases. The median follow-up was 8.25 months. Among the 22 patients evaluable for efficacy, the ORR was 90.91% (20/22), including a complete response (CR) rate of 36.4% and a partial response (PR) rate of 54.5%. The DCR was 100%. No disease progression had been observed during the study period by the data cutoff, and median PFS had not been reached.
These results suggest that this treatment combination warrants further attention for short-term tumor control, particularly given the depth of response observed following the integration of systemic treatment and definitive local therapy. However, this remains a small, single-arm Phase II study with limited follow-up. Longer-term outcomes, including PFS and overall survival (OS), require further follow-up and validation in larger studies.
Oncology Frontier: This study combined QL1706, a PD-1/CTLA-4 bispecific antibody, with chemotherapy and definitive radiotherapy as first-line treatment for oligometastatic cervical cancer. Considering the characteristics of bispecific immunotherapy, how do you view the potential role of these agents in the comprehensive treatment of cervical cancer?
Professor Peng Xie: Cervical cancer is closely associated with viral infection and the tumor immune microenvironment. The role of immunotherapy in recurrent or metastatic cervical cancer has become increasingly established. QL1706 simultaneously targets the PD-1 and CTLA-4 immune checkpoint pathways. In theory, this approach may facilitate T-cell activation while relieving immunosuppression. Compared with blocking the PD-1 pathway alone, modulation of both pathways may produce a more robust immune response in some patients, although this hypothesis still requires clinical validation.
In this study, QL1706 was not administered as a standalone treatment. Instead, it was incorporated into a continuous treatment strategy: chemotherapy was given initially to reduce tumor burden as quickly as possible; definitive radiotherapy was then introduced to strengthen local control; and immunotherapy maintenance was continued after radiotherapy to prolong disease control. The key to treating oligometastatic cervical cancer is not simply to emphasize one particular drug, but to determine whether systemic therapy, local treatment, and maintenance therapy can be integrated in an appropriate sequence.
In terms of treatment sequencing, chemotherapy is intended to rapidly reduce tumor burden and create favorable conditions for local treatment. Radiotherapy addresses residual or visible lesions, while immunotherapy maintenance aims to sustain the disease control achieved through earlier treatment. These modalities are not simply added together. In clinical practice, treatment needs to be adjusted dynamically according to tumor regression, blood counts, and organ function. For patients with oligometastatic disease, the timely delivery of local treatment and the ability to complete the planned radiotherapy may be just as important as the choice of drug itself.
The current findings also raise several clinical questions: Which patients are more likely to benefit from this combination? Is there a more appropriate sequence for immunotherapy and radiotherapy? And how can response rates be improved while controlling hematologic toxicity and immune-related adverse events?
Oncology Frontier: The overall safety profile of the combination regimen in this study was manageable, with adverse events primarily involving hematologic toxicity and immune-related adverse events. How should clinicians ensure comprehensive management throughout treatment when implementing this type of combination therapy?
Professor Peng Xie: This type of regimen involves multiple treatment stages, so safety management must begin before treatment starts. Before enrollment, patients should undergo assessments of performance status, liver and kidney function, bone marrow reserve, previous treatment history, and whether recurrent or metastatic lesions are suitable for definitive irradiation. During treatment, changes in blood counts, infection risk, and organ function should be closely monitored to determine whether supportive care, chemotherapy dose adjustments, or modifications to the treatment schedule are necessary.
The treatment team needs to coordinate in advance rather than waiting until toxicities emerge before deciding how to manage them. For example, persistent declines in blood counts during chemotherapy may delay the initiation of radiotherapy. If immune-related toxicities are not recognized promptly, they may also interfere with subsequent maintenance treatment. Therefore, the criteria for transitioning between treatment stages should be clearly established before therapy begins. Complete blood counts, liver and kidney function, and thyroid function should be reassessed at regular intervals during treatment, and changes in symptoms should also inform clinical decisions. This approach can help minimize treatment interruptions and enable patients to complete the planned comprehensive treatment pathway.
In this study, grade ≥3 adverse events were primarily hematologic toxicities, including lymphocyte count decreases in 20/28 patients (71.4%), white blood cell count decreases in 10/28 patients (35.7%), and neutrophil count decreases in 9/28 patients (32.1%). Clinicians need to monitor complete blood counts closely, assess infection risk, and provide white blood cell growth factor support and anti-infective treatment when necessary. During definitive radiotherapy, bone marrow reserve and overall patient condition also influence whether treatment can proceed as planned.
Immune-related adverse events also require monitoring. The study reported grade 1 pneumonitis in 2/28 patients (7.1%), recurrence of psoriasis in 1/28 patients (3.6%), renal failure in 1/28 patients (3.6%), and thyroid dysfunction in 9/28 patients (32.1%). No treatment-related deaths occurred.
Overall, the safety profile observed in this study was manageable. Close collaboration among members of the treatment team, together with timely recognition and management of toxicities, is essential to help patients complete the planned treatment pathway.
Expert Commentary
Professor Peng Xie noted that the value of treating oligometastatic cervical cancer lies in preserving the possibility of long-term disease control and even cure for selected patients. This study provides a treatment framework of “systemic therapy–definitive radiotherapy–immunotherapy maintenance,” with encouraging early efficacy findings. However, longer follow-up and larger studies are still needed to determine whether this approach offers long-term survival benefits.
In clinical practice, the treatment regimen, timing of local therapy, and toxicity management are all equally important. Whether patients can safely complete each stage of treatment ultimately determines whether the comprehensive treatment strategy can deliver its intended benefit.
Professor Peng Xie
